132 related articles for article (PubMed ID: 36103329)
21. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
22. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
23. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.
Maeda D; Ota S; Takazawa Y; Ohashi K; Mori M; Imamura T; Nakagawa S; Yano T; Taketani Y; Fukayama M
Virchows Arch; 2010 Nov; 457(5):597-608. PubMed ID: 20872013
[TBL] [Abstract][Full Text] [Related]
24. The histologic subtype of ovarian tumors affects the detection rate by pelvic washings.
Fadare O; Mariappan MR; Wang S; Hileeto D; McAlpine J; Rimm DL
Cancer; 2004 Jun; 102(3):150-6. PubMed ID: 15211473
[TBL] [Abstract][Full Text] [Related]
25. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
26. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
27. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
Malpica A; Deavers MT
Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
[TBL] [Abstract][Full Text] [Related]
28. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
29. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
Ren S; Klump W
Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical Characterization Improves the Reproducibility of the Histological Diagnosis of Ovarian Carcinoma.
Missaoui N; Salhi S; Bdioui A; Mestiri S; Abdessayed N; Mokni M; Yacoubi MT
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2545-2551. PubMed ID: 30256049
[TBL] [Abstract][Full Text] [Related]
31. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens.
Satturwar S; Shaker N; Sinclair W; Shen R; Parwani AV; Ding Q; Li Z
Cancer Cytopathol; 2023 Jul; 131(7):465-470. PubMed ID: 37195085
[TBL] [Abstract][Full Text] [Related]
32. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.
Hashmi AA; Naz S; Edhi MM; Faridi N; Hussain SD; Mumtaz S; Khan M
World J Surg Oncol; 2016 Mar; 14():91. PubMed ID: 27029917
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Davidson B; Elstrand MB
Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
[TBL] [Abstract][Full Text] [Related]
35. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary.
Kandalaft PL; Gown AM; Isacson C
Am J Clin Pathol; 2014 Dec; 142(6):830-6. PubMed ID: 25389337
[TBL] [Abstract][Full Text] [Related]
36. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
37. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
38. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
39. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
40. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]